likely to develop certain chronic pain conditions, as are older people, although age may function as a protective factor in some instances. The influence of genetics is supported by twin and population-based studies, which clearly indicate that painful conditions and acute pain sensitivity per se are heritable (see ref. 5 for a recent review). Other risk factors relate to an individual's personality and psychosocial environment. Not surprisingly, previous pain history predicts future pain development. However, adverse life events, such as stress and unemployment, as well as personality traits, a tendency to catastrophize and depressive illness, negatively affect long-term pain outcome. Although the presence of these links is not in doubt, cause and effect often remain unclear.
It is not our intention to discuss these risk factors in any depth (the interested reader is referred to refs. 1-3), but rather to consider the mechanisms by which they may affect the emergence or maintenance of chronic pain (Fig. 1) . Their elucidation might not only help to identify individuals at risk, but also deepen our understanding of persistent pain conditions and potentially open up new avenues for the development of preventative and targeted treatment regimes.
Genetic risk
Human genetic studies have had a marked effect on many branches of medical science, including pain. There have been two distinct approaches, which this Review will discuss in turn: linkage analysis in families suffering from rare Mendelian disorders in which single gene mutations cause profound loss or gain of function, and association studies in large cohorts, in which genetic variants are correlated with differences in a particular trait, such as height or, in the current context, pain sensitivity.
A number of families have been identified that show monogenic patterns of inheritance for sometimes dramatic pain phenotypes, such as complete analgesia or extreme pain. Congenital analgesia is rare, with an estimated prevalence of about one in a million, and the precise symptoms and underlying genetic mutations vary between families 6 . Yet, the study of these families has not only revealed the mechanism by which risk is conferred in these particular individuals, but has also deepened our understanding of chronic pain in the general population.
For instance, congenital insensitivity to pain with anhidrosis (HSAN-IV, CIPA) is a result of recessive loss-of-function mutations in the TRKA receptor gene (see ref. 7 for review). This result helped to consolidate pre-clinical findings that have implicated TRKA and its ligand NGF in nociceptor sensitization 8 and has eventually led to both targets being pursued by the drug development industry, with promising results: tanezumab, an NGF antibody, has reached phase III of clinical trials for the treatment of hip and knee osteoarthritis and may also be effective in other chronic pain conditions, such as back pain and interstitial cystitis (see http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Arthrit isAdvisoryCommittee/UCM295205.pdf). Similarly, a linkage study of a Chinese family in 2004 identified a previously unknown target in primary erythermalgia, the sodium channel subunit Na v 1.7 (SCN9A). Mutations in SCN9A can result in indifference to pain and paroxysmal extreme pain 9 . Animal studies have since confirmed the presence of Na v 1.7 in 85% of nociceptors and its importance for processing both mechanical and inflammatory painful stimuli 9 . Several sodium channel blockers are now in phase IIa clinical trials to test their efficacy against pain of diverse etiologies. Finally and most recently, another sodium channel subunit has emerged as a potential target, with a gain-of-function mutation having been reported in Na v 1.9 (SCN11A) as another cause of pain insensitivity 7 .
In contrast with rare Mendelian conditions, the study of pain genetics in the wider community presents a more complex picture. What everyone can agree on is that a sizable degree of risk is indeed accounted for by genetics: most heritability estimates from twin studies range from 13-60% depending on the pain phenotype and cohort examined 5 , and heritability can reach 30% for severe chronic pain even in the general population 10 . As to identifying the genes responsible, the pain field has mostly conducted case-control candidate gene association studies that have revealed a wide variety of risk alleles. Loci for which a positive association has been reported are involved in neurotransmitter systems (COMT, OPRM1, GCH1, 5HTR2A, ADRB2), ion channel function (KCNS1, CACNA2D3) and immune function (IL1, TNF) 6 . For most of these, the mechanistic steps by which any single nucleotide polymorphism (SNP) or haplotype identified might confer risk toward chronic pain in later life are not very clear, although more functional, pre-clinical studies are beginning to emerge (for example, see refs. 11,12) . More worryingly, as summarized recently 6 , results are often not replicable, not least because of issues with poor phenotyping, population stratification and sample size.
Recently, genome-wide association studies (GWASs) have been employed, providing unbiased screening of common variants. However, many of the GWASs published, despite examining painful disorders such as osteoarthritis 13 , lumbar disc degeneration 14 or endometriosis 15 , barely mention pain, let alone measure it directly. There are notable exceptions: several large-scale GWASs and a metaanalysis in migraine research 16 , a study of molar extraction, which only examined acute post-surgical pain and may have been somewhat underpowered with only 100 participants 17 , a study of opioid sensitivity that revealed a SNP close to the CREB1 gene 18 , and a GWAS meta-analysis of chronic widespread pain syndrome. The latter study merged and re-analyzed previously collected genotyping data to identify previously unknown variants in two genes (CCT5 and FAM173B), the expression of which was found to be altered in a mouse model of pain 19 .
What could be improved to help elucidate the genetic risk factors for chronic pain? A fundamental question that remains and the answer to which will greatly influence study design is whether many genes Total incidence of neuropathy  48  Painful neuropathy  34   Postsurgical pain  159,000  Amputation  30-50  479,000  Breast surgery  20-30  Unknown  Thoracotomy  30-40  609,000  Inguinal hernia repair  10  598,000  Bypass surgery  30-50  220,000  Caesarean section  10   Lower back pain  448  Pain 5 years after first presentation: prospective study  36.9  180  Pain 12 months after initial consultation: prospective study  34   Neck pain  5,277 Incidence of chronic neck pain in cohort of patients reporting at least one episode of acute neck pain: prospective study
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Only a minority of acute pain sufferers, disease affected and surgical patients will develop chronic pain [1] [2] [3] . npg are linked to nociception and pain per se (such as SCN9A). There are two not mutually exclusive alternatives. First, risk haplotypes might differ according to the various underlying painful disorders, and future research effort should therefore focus on GWASs such as the above-mentioned study of osteoarthritis. Conversely, genes might be more strongly linked to the various nociceptive modalities such as thermal or mechanical hypersensitivity, independent of the original source of the pain. Evidence from animal models indicates that modality can be more important than the underlying condition, but data from humans remains contradictory 6 . In either case, rigorous, standardized phenotyping, for example, using quantitative sensory testing, will be required to advance the field, not only for accurate pain modality assessments, but to help generate homogeneous cohorts with little stratification. Similarly, family-based designs provide greater protection from the latter. They can also facilitate the exploration of rare variants by helping to distinguish them from sequencing errors, as evinced by a recent exome sequencing study 20 that found that heat pain sensitivity in twin pairs was associated with a regulatory network around angiotensin II. Taking into account interactions, both on a phenotype and genotype level, could make another improvement. Studies often neglect to collect phenotype data on confounding factors that could modulate pain, such as anxiety and depression and therefore are in danger of wrongly assigning risk to biological pathways unrelated to pain. Moreover, epistatic effects, that is, interactions between genes, as well as interactions between genes and the environment are commonly ignored, although studies in mice 21 and more recently humans 22 clearly indicate that they can have an important role.
Finally, research into the genetics of pain should not stop at identifying the putative causal allele. Although still rare, there are studies that have moved into the functional realm with evidencebased examination of potential biological consequences. A genomewide linkage analysis in mice identified a haplotype in the P2RX7 gene that was associated with strain-specific variations in hypersensitivity to mechanical stimuli. The authors then carried out pre-clinical work and found that the risk haplotype was associated with a structural change in the ion channel pore of P2RX7, which had consequences for nociceptive processing. Lastly, they identified a corresponding haplotype in humans that was associated with two distinct pain syndromes (post-surgical pain and osteoarthritis) 23 . Other instances in which studies bridge the mechanistic gap between gene and behavior can be found in the brain imaging literature 24 , where individual genotypes have been related to changes in activity in relevant cortical areas. Thus, functional polymorphisms that are weakly related to chronic pain syndromes might be strongly related to the integrity of the underlying neural systems as revealed by brain imaging. However, it is not easy to ascribe causality at this stage. Studies have focused on polymorphisms that influence catecholamine and serotonergic neurotransmission (that is, COMT and the serotonin transporter gene SLC6A4; see ref. 24 and references therein), reflecting a link to reward and the descending pain modulatory system (DPMS), which will be discussed in more detail below. COMT appears to be more involved in models of chronic and tonic, rather than acute, pain and has been reported to have widespread effects on affective and cognitive tasks mediated by the prefrontal cortex (PFC). However, SNPs in the gene could not be convincingly related to overall pain risk in some genetic studies 24 and may therefore only be relevant during the expression rather than the development of chronic pain as a result of the PFC-related effects. In contrast, imaging studies of serotonin receptor and transporter systems may be better able to identify potential vulnerability. Neuroimaging studies that associate SLC6A4 with the experience of pain in healthy individuals and patients are emerging (see ref. 24 for a review). In addition, genetic variation in SLC6A4 has been linked to altered brain frontallimbic network reactivity to relevant environmental stimuli and a predisposition to several neuropsychiatric disorders. In the anxiety literature, it is interesting how many parallels with pain exist in terms of genetic polymorphisms and environmental stressors influencing PFC-amygdala networks (see ref. 25 and references therein) that might confer vulnerability to both conditions.
Pain vulnerability: epigenetics
In the previous section, we examined how differences between individuals' DNA sequences can predispose toward pain, but what about differences in how this sequence is used? The study of epigenetics includes phenomena such as DNA methylation and histone modifications ( Fig. 2) , which do not affect the sequence itself, but can affect gene function, a kind of biological annotation mechanism. Epigenetic signatures determine lineage specificity during development and can be stably maintained throughout the life of an organism and, in some cases, even across generations, for example, in the case of imprinting of parental alleles 26 . Figure 2 Polymorphisms in the DNA sequence and epigenetic mechanisms such as DNA methylation and histone modifications determine some risk from birth that can lead to transcriptome and connectivity differences. Shown here is a schematic of DNA with two SNPs (red) and modification by methylation (Me) at a CpG island. The DNA is wrapped around a histone octamer consisting of two H2A-H2B histone dimers and one H3-H4 histone tetramer, the lysine residues of which can be biochemically modified. Represented here are phosphorylation (P), acetylation (Ac) and methylation. Examples for each mechanism can be found in the primary literature, in particular refs. 14,23,33. Arrows represent correlational links as opposed to clear causal connections. DMR, differentially methylated region; HDAC, histone deacetylase.
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In chronic pain, some associations with epigenetic markers have recently been identified. Altered methylation was observed at the PARK2 locus in patients with lumbar disc degeneration 14 . Moreover, back pain was also found to be linked to methylation changes at the SPARC gene in both humans and mice 27 .
It is currently not clear how much of this putative variation is present from birth and how much is acquired later. Until a decade ago, dogma on DNA methylation maintained that, in healthy tissues, the modification remained mostly unaltered postnatally. However, recent research has identified mechanisms for active DNA demethylation 28 , and accumulating evidence suggests that both DNA methylation and histone modifications can change rapidly in an adult organism, even in a postmitotic environment 29 . Epigenetic modifications may therefore provide a manner in which environmental influences can leave a long-term imprint on gene expression. The idea, first proposed by so-called behavioral epigeneticists, has encountered a healthy level of skepticism 30 , but is gaining traction from research in many other fields, including normal brain function, aging, and a variety of disorders such as neurodegeneration and chronic pain 31, 32 . In the current context, the hypothesis is that injury or disease might result in a type of molecular memory that could affect a person's risk of developing chronic pain at a later stage.
Evidence in support of this hypothesis is slowly starting to emerge. Histone modifications seem to be involved in both inflammatory and neuropathic pain conditions, as evinced by the analgesic effect of histone deacetylase inhibitors-drugs that interfere with the removal of histone acetyl groups 32, 33 . There are also indications that changes in histone modification may correlate with changes of expression of relevant genes 5 , although the direction of causality remains unclear, as does the biological relevance of histone marks at individual genetic loci 34 . In the case of DNA methylation, one early drug study, using a DNA methyltransferase inhibitor, reported alleviation of hypersensitivity after chronic constriction injury 35 . However, these results are inconclusive, as the study used a compound that cannot act on postmitotic cells 36 . Correlational work has been carried out, linking global changes in DNA methylation in the PFC and amygdala to peripheral nerve injury 37 and examining local alterations in DNA methylation at several genetic loci 5, 38 . Again, cause and consequence are unknown. Finally, the most substantial body of work has been conducted around the methyl CpG-binding protein 2 (MECP2), an enzyme that is crucial to neuronal development, which binds to methylated CpGs. MEPC2 is downregulated after nerve injury in the dorsal root ganglia, its targets are upregulated in the spinal cord after peripheral inflammation 39 and mutations in its sequence can lead to abnormal pain sensations in patients 40 . A recent study by Skene et al. suggests that MECP2 binds neuronal DNA very widely and might function as a global regulator of chromatin remodeling, recruiting co-repressors to the right place at the right time, thereby reducing transcriptional noise 41 . One could hypothesize that even subtle differences in MECP2 function might have noticeable consequences and could, at least in theory, be at the root of inter-individual differences in phenotype.
To summarize, the literature on pain and epigenetics is still in its infancy. Only a small number of papers have been published and, not surprisingly for such a new field, some of them still suffer from basic technical issues. These include a lack of negative controls for chromatin immunoprecipitation and the use of compounds better suited to dividing cell systems. What does seem clear is that persistent pain states are associated with epigenetic modulation of histones or DNA and that drugs targeting epigenetic processes can modify pain processing. What is unknown is whether long-term vulnerability or resilience for pain arises from these processes. In the future, the cell-type specificity of epigenetic marks will need to be addressed, especially in terms of DNA methylation studies in humans. In the case of histone modifications, timescales, especially in postmitotic cells, and precise function still need to be elucidated. It may be worthwhile to bear in mind evolutionary conservation 42 and the high degree of redundancy when considering their biological importance. Long-term risk for chronic pain may be more likely to be conferred by differences in DNA methylation, arguably one of the most stable epigenetic marks. The focus should be on studying cell-specific models in which causality can be established. New compounds for the study of epigenetics are continually emerging and may greatly aid this work.
Priming mechanisms
In the previous section, we argued that epigenetic mechanisms might confer risk for chronic pain by functioning as a type of molecular memory-a record of prior injury or disease that may adversely affect future responses to similar insults. But is there any evidence that such a priming mechanism does indeed exist in chronic pain? There are several lines of research that indicate that early life stressors or even previous injury in adulthood can make an animal more vulnerable to develop persistent pain. We will discuss postnatal experiences and adult priming in turn.
Pain exposure in early life can lead to heightened pain sensitivity once the animal has fully developed. This has been shown for diverse stimuli, such as neonatal chronic foot shock, inflammation and incision (see ref. 43 and references therein). Moreover, not just pain, but also early-life stress seems to be sufficient to induce hypersensitivity in later life. Thus, maternal separation can lead to increased visceral hypersensitivity in adult rats 44 and mice 45 . Many potential mechanisms have been proposed for these phenomena, including alterations to the opioid system, increased axonal sprouting or NGF-induced neuronal plasticity, involvement of the hypothalamic-pituitary-adrenal axis and of spinal microglia 43, 46 . Most recently, imaging data have confirmed these pre-clinical findings. Studies on preterm infants examined at various time points after hospital discharge confirm that alterations in brain processing occur and that this affects cognitive outcomes 47 and brain reactivity specifically to painful events 48 .
In adulthood, priming has been induced using low-dose inflammatory stimuli that ordinarily only result in short-lasting hypersensitivity. When a rat is administered two consecutive low doses, the second one will cause longer lasting (days rather than hours) and more pronounced hypersensitivity (Fig. 3) . Priming can be observed with diverse inflammatory mediators, such as prostaglandin E 2 , serotonin and NGF, and with stress caused by unpredictable sound 49 . The phenomenon has also been reported with other paradigms employing repeated nerve injury, stress before nerve injury or formalinand injury-induced enhancement of pain following intrathecal lipopolysaccharide injection (see ref. 50 and references therein). Mechanistic explorations of priming fall into two main categories, focusing on peripheral afferents and spinal microglia, respectively. Experiments from the Levine laboratory indicate that the priming stimulus activates an additional PKCε-mediated second messenger cascade in isolectin B4-positive peripheral afferents. This in turn recruits the cytoplasmic polyadenylation element-binding protein (Cpeb), a regulator of protein translation, which is hypothesized to render nociceptors more responsive to pro-inflammatory cytokines 51 . Another study examined alterations in microglial responses in the spinal cord following the induction of priming 50 . For example, minocycline, an inhibitor of microglial activation, was found to reduce priming induced by lipopolysaccharide injections in rats. 'Vulnerable' brain networks Having discussed possible molecular and cellular risk factors, it is important to now ask whether brain networks are involved. Our understanding of the brain's general role in pain experiences is discussed more fully in Box 1. However, the concept that differences in brain function relate to both individual variances in behavior and perhaps a vulnerability toward or resilience against causing a diseased or perhaps chronic pain state is now being actively discussed both inside and outside of the pain field 25, 52, 53 . Data are relatively sparse, as firm agreement on what a normal brain looks like and how networks relate to mechanisms is lacking for most conditions. Moreover, the traditional approach in brain imaging is to group average results, thereby smoothing out any variances. Despite these caveats, several studies have reported inter-individual differences in brain activity, structure, wiring and chemistry. They specifically relate to endogenous modulatory capacity 54 , psychological traits 55 , pain thresholds in healthy subjects 56, 57 and patients 58 , clinical descriptors 59 , or opioid analgesic outcomes 60 . What remains unclear is whether these brain correlates of trait and behavioral variance in healthy subjects translate into an increased likelihood for developing chronic pain. Understanding whether changes in brain networks are consequential to having chronic pain or causal in producing it is very difficult and relies on detailed, longitudinal knowledge of biological and environmental subject variables. We lack a definitive answer, but data discussed here suggest there might be several candidate causal networks (Fig. 4) . Figure 3 Adverse events, such as stress, injury or disease, can challenge and modify the hardwired system at different levels, including epigenetic, cell biological, and systems and network levels. Altered histone methylation has been linked to depression 100 and could also be relevant in other conditions, such as chronic pain. A cellular mechanism has been put forth to explain the phenomenon of priming 49 : repeated administration of inflammatory mediators results in increased pain intensity and duration. This may be a result of altered second messenger cascades and subsequent transcriptional changes. Finally, neonatal incision of the hindpaw can lead to altered innervation and glial response patterns, resulting in increased pain sensitivity in adulthood 43 . PGE2, prostaglandin E 2 ; EP-R, ephrin receptor; PCK ε , protein kinase C epsilon; CPEB, cytoplasmic polyadenylation element-binding protein.
It is tempting to hypothesize that all networks subserving the emergence of pain perception and its modulation might contribute to the vulnerability toward or resilience against chronic pain development. However, most data come from pain studies in healthy controls and use repeated and short-lasting stimuli that are more akin to acute pain. The networks identified might not always relate to chronic pain or might be incomplete, as evinced in recent studies 93 . Advances in our ability to image within an individual ongoing or tonic pain states more relevant in chronic pain have occurred and look promising despite the technical and analytical challenges 94 . Such studies will provide additional opportunities to identify relevant vulnerable networks. Alongside these identified caveats, it should also be noted that brain imaging is not simply a surrogate objective measure of pain ratings, but is instead a very powerful tool for determining why a subject experiences their pain in a specific way. It can shed light on the many mechanisms and factors that ultimately give rise to the individual experience of pain-namely, an identifiable and measurable nociceptive drive, the immediate context, a person's emotional and cognitive state-and perhaps, in the future, an individual's brain vulnerability.
Interpretation is key and most studies have been careful to use models that dissect the activity from a complex network of responsive brain regions to associate regional activity with the various components that make up the multidimensional pain experience. Thus, nonspecific responses in regions involved with, for example, attention, expectation, anxiety and other emotions, can be better understood neuroanatomically and in light of their contribution to pain experiences 68, 95, 96 . The fact that many of the brain regions that are found to be active are not pain specific is not a new concept, and recent studies again highlight this point, but argue for the nonspecificity to be considered instead as a brain network encoding the saliency of pain as a result of its predominance amongst many stimuli 97 .
The advent of non-invasive tools has nevertheless been invaluable in increasing our understanding of the brain regions that subserve the private, multidimensional experience of pain. The current framework for the neural basis of pain perception includes a large bilateral network that is potentially available for activation (Fig. 4) . Its different components can show varying levels of activation and can be recruited for activation (or not) in a dynamic fashion contingent on nociceptive drive, context, cognition and emotion. If any of these factors change, the same nociceptive input can produce a different cerebral signature in the same subject, even stimulus by stimulus. Thus, the behavioral reaction to such pain experiences is very efficient, as it is based on a rapid and adaptive brain response that is tailored to specific situations 68 .
In addition, this large network can be broken down into multiple interacting pain matrices of increasing neural hierarchy, as recently put forward by Garcia-Larrea and Peyron 98 . Multivariate pattern analysis has been used in an attempt to simplify this complex set of interacting networks to a core set of brain regions or a generalizable 'pain signature'. Such approaches identify the following areas as key to experiencing pain: the thalamus, the posterior and anterior insulae, the secondary somatosensory cortex, the anterior cingulate cortex, and the periaqueductal gray matter 99 -still a complex pattern with the specificity question unresolved. Whether network differences in the acute or chronic pain networks are causal toward or consequential of chronic pain is not yet known. However, data from recent studies suggest that several networks, including the reward-motivation learning and DPMS, might be aberrant pre-injury and confer a vulnerability toward developing chronic, persistent pain.
Box 1 Brain networks for pain and its modulation npg
We will focus our discussions on the rewardmotivation-learning network and the DPMS.
The reward-motivation learning network A recent study 61 comes closest to being the 'pre-to-post injury' longitudinal imaging study that is ideally needed. The authors performed a longitudinal brain imaging study of subacute back pain patients over the course of 1 year using a battery of brain imaging measures from the acute pain phase onwards. Pain persisted in 12 patients at the end of the year, whereas 12 patients had improved. In the persistent pain group, gray matter density was decreased, as has been shown to occur in other chronic pain conditions. Of particular relevance are the results from the first 'baseline' imaging session during the acute pain phase. Here, greater functional connectivity or 'coupling' of the nucleus accumbens (NAc) with the PFC predicted pain persistence by more than 80%. This implies that corticostriatal circuitry might be causally involved in the transition from acute to chronic pain. Notably, this increased coupling remained constant throughout the transition to chronic pain, despite gray matter density decreasing in the NAc. In an additional analysis, the authors discovered brain white matter connectivity differences in the PFC at an early time point, which was again more pronounced in the group that went on to develop chronic pain. These changes may reflect structural vulnerabilities, as measured by diffusion tensor imaging and fractional anisotropy calculations. Importantly, as with the functional connectivity measures, these white matter fractional anisotropy differences accurately predicted pain persistence over the next year, and this was validated in a second cohort of subacute back pain patients 62 . Although it is unknown whether these differences in function and structure were present pre-injury and therefore represent an a priori risk for pain, this study nevertheless highlights how the brain's rewardmotivational learning circuitry is potentially relevant in predicting the transition from acute to chronic pain. In an earlier study, the authors had already reported results that hinted at a possible bias in the reward network before chronic pain development 63 . They found differential NAc responses to acute noxious thermal stimuli in controls and chronic back pain patients, implying that an altered valence to acute pain exists between patients and controls.
Indeed, studies in the past have noted the relevance of reward circuitry in pain 64 , and other related networks, such as those relevant to dopaminergic signaling, have also been described. Thus, patients with fibromyalgia have disrupted dopaminergic reactivity 65 . Furthermore, placebo analgesia in healthy controls can be predicted by dopaminerelated traits, with magnitude of analgesia correlated to gray matter density in the insula, ventral striatum and PFC 66 . A link between the ability to experience analgesia and the brain reward network is also supported by findings from our laboratory. Baseline responses to a painful stimulus were found in reward networks, involving, for example, the ventral tegmental area and the NAc. This baseline activity was predictive of both subsequent opioid induced behavioral analgesia and its neural expression via the DPMS 60 .
Despite these results, the precise role of the reward-motivation learning system in pain remains unclear and may depend on context. We found that the hedonic value of pain could be 'flipped' , fundamentally altering its emotional value from threat to reward. This change was mediated by activity in reward regions working in concert with the DPMS 67 , providing further evidence for the importance of these networks in pain appraisal, a key feature of ongoing, chronic pain states. Dispositional optimism and pessimism, key trait factors relevant in pain, powerfully influence unexpected reward/analgesia outcomes, with diametrically opposite NAc activity distinguishing the pessimists from optimists 67 . Combined with data already discussed, it seems likely that transition to and continuation of chronic pain is dependent on the state of motivational/learning and reward mesolimbic-prefrontal circuitry of the brain.
The DPMS
The DPMS is a powerful network that regulates nociceptive processing in the dorsal horn of the spinal cord and thereby controls which signals enter the brain. As such, it is important in influencing what pain you ultimately experience 68, 69 . The brainstem's component of the DPMS involves, among other nuclei, the periaqueductal gray and the rostral ventromedial medulla (RVM). There is bidirectional central control of nociception that can either alleviate pain in situations in which antinociception is necessary for survival (driven by 'off ' cells), as in sporting competition or battle, or can facilitate nociceptive processing (driven by 'on' cells), thereby contributing to the maintenance of heightened pain states. This was confirmed recently in several brainstem-imaging studies of chronic pain and central sensitization, a key dorsal horn event that amplifies incoming nociceptive inputs 70 . The anterior cingulate cortex, amygdalae and hypothalamus are also part of the DPMS, and these connections to the brainstem are the means by which cognitive and emotional variables interact with nociceptive processing to influence the resultant pain experienced, as shown by a wealth of brain and spinal cord npg imaging studies 71, 72 . Neurochemically, the DPMS releases noradrenaline and 5-hydroxytryptamine (5-HT) onto spinal circuits. Noradrenaline acts through its inhibitory alpha-2 adrenoceptor to inhibit, whereas 5-HT has bidirectional effects, inhibiting via 5-HT1 receptors and facilitating when 5-HT2 or 5-HT3 receptors are activated at spinal levels 68 . The polymorphisms in SLC6A4 discussed earlier that influence pain outcomes are likely mediated via this system. Furthermore, disturbances in sleep or mood, as well as early life stressors that are known to relate to neuroticism and anxiety, could have profound developmental influences on this key system via alterations in the coupling of the amygdala-PFC network to the brainstem nuclei. Such an unfavorable imbalance in inhibitory and facilitatory (that is, off and on cells) drive could therefore predispose individuals toward developing persistent pain. Supporting data for this hypothesis comes from both recent animal and human studies. One experiment measured patients' responses to painful stimuli in a laboratory setting and showed that results from certain tests could be used to predict acute pain after thoracotomy surgery 73 . Most predictive was pain temporal summation, that is, an individual's level of pain in response to a series of heat stimuli. This measure is thought to be mediated by central processes such as the DPMS and may represent neuroplasticity potential. An alternative manipulation that is thought to tap into latent DPMS function via diffuse noxious inhibitory control (DNIC) mechanisms is conditioned pain modulation 74 , which can be used to predict lower risk of chronic post-thoracotomy pain 75 . A more recent study found that poor DNIC efficiency predicts duloxetine efficacy in painful diabetic neuropathy 76 . Duloxetine targeted the serotonergic and noradrenergic brainstem systems central to the DPMS and even corrected the aberrant DNIC efficiency. Although no imaging counterpart to these studies has been performed to verify the neural network at risk, it is highly likely that defects in the DPMS inhibitory and facilitatory arms will be identified and related to chronic pain transition.
In fact, animal studies suggest that this might be the case. Porreca's group has collected evidence to suggest that changes in the DPMS are crucial to the persistent nature of pain in models of nerve injury. They found that post-injury decreases in descending inhibitory and increases in descending facilitatory activity on dorsal horn processing strongly influence whether chronic pain behavior is maintained (and opposite for improved pain symptoms) 77, 78 . Knowing whether such an imbalance exists prior to injury is important, and evidence from neonatal rat studies might shed light on this issue. Hathway and colleagues showed that the RVM exclusively facilitated spinal pain transmission in rats up to postnatal day 21. However, after this age (postnatal day 28 to adult), its influence shifted to biphasic facilitation and inhibition 79 . These data hint at the possibility that, should there be damage at a critical period of development (for example, through stress or injury), it could permanently influence the 'set point' of the DPMS and, possibly, pain network maturation. The authors also found that there is another critical period for DPMS functioning during preadolescence 80 , where a developmental transition from RVM descending facilitation to inhibition of pain occurs, which is determined by activity in central opioid networks. Their subsequent work showing how early life nerve injury produces a mechanical hypersensitivity only later in life is intriguing in light of these findings 81 .
In sum, these results lead us to hypothesize that early life injury may create an imbalance in the DPMS, leading to inappropriate inhibition or facilitation of ascending pain signals. This in turn may create vulnerability and, as such, affect the maintenance of chronic pain states.
Hormones and the adolescent brain: a vulnerable time? As noted from the animal studies above, there is a critical period of development during preadolescence. Although imaging studies examining how hormones generally influence brain activity are scarce, those published to date hint at the possibility that adolescent brains might be rendered vulnerable at this stage of hormonal upheaval 82 . Results support a link between the stress system and the DPMS, with one study showing that testosterone influences DPMS activity during altered estradiol states 83 . Other studies have shown that repeated episodes of pain associated with menstruation throughout adolescence and early adulthood can be linked to central sensitization and alterations in brain function, structure and duration 84, 85 .
A related line of research explored how sex differences might confer differential vulnerability, and several studies found substantial sex-related structural differences in pain-related regions 86 . This whole area is fertile for further exploration, and we believe that it will be increasingly important in the effort to answer brain pain vulnerability-related questions.
Can we outline a causal trajectory from aberrant brain activity? As mentioned above, a major caveat of the literature to date is its failure to identify causality. In addition to the studies already described that focus on the reward and DPMS networks, other studies have also tried to address this issue. These studies have been restricted to the injured state, but have taken a different approach and attempted to characterize whether non-pain-related features are present that correlate with differential brain activity or structure compared with controls. For instance, researchers have examined the contribution of a potential pre-existing vulnerability resulting from neuroticism, a stable personality trait characterized by a propensity for negative affect. Neuroticism was found to be positively correlated with increased thickness in the orbitofrontal cortex, an area linked to pain associated with temporomandibular disease 87 . Similarly, a correlation between white matter connectivity strength and neuroticism has been found in irritable bowel syndrome. And finally, irritable bowel syndrome patients with a tendency to catastrophize their pain showed reduced dorsolateral PFC thickness and increased hypothalamic gray matter (see ref. 88 and references therein). These studies suggest that an individual's personality might be associated with differential brain structure and connectivity in areas relevant to chronic pain and that this might constitute vulnerability before the development of the condition that contributes to emergence and/or maintenance of the chronic pain state.
An additional phenomenon that has been examined in this context is attentional focus in the face of competing stimuli (for example, having to perform a challenging cognitive task while experiencing pain). Thus, a recent study from Erpelding and Davis 89 classified subjects as 'pain focused' or 'attention focused' . Whether their data reflect vulnerability toward developing chronic pain remains to be determined, but promising parallels can be drawn to the anxiety literature. Frontal brain regions are involved in attentional regulation of emotionally and non-emotionally salient stimuli, including the dorsal and ventrolateral PFC and the rostral and dorsal anterior cingulate cortices. Some of these areas were differentially regulated in Erpelding and Davis's experiment, suggesting a potential vulnerability in emotion regulation.
Conclusions
The literature leaves little doubt that certain groups of people are more vulnerable to develop chronic pain conditions. Evidence and viable hypotheses can be found as to why genetics and adverse priming npg events, such as a prior injury or stressful environmental influences, may confer increased risk. The latter may involve changes to neuronal architecture and molecular processes via epigenetic modulation that ultimately lead to changes in cortical wiring, brain chemistry, function and structure. Whether measureable alterations in brain function precede and/or follow the onset of chronic pain, they might lead to a vicious cycle in which vulnerability leads to non-resilience to additional factors arising from the chronic pain state. Possible support for this comes from several studies showing accelerated gray matter loss in chronic pain patients, as if they were undergoing premature aging 90 .
The characterization of brain imaging signatures in pain-free individuals before any injury will be crucial if we are to identify the relevant vulnerable networks. Two current large-scale projects afford this opportunity: the UK's Imaging Biobank (http://www. ukbiobank.ac.uk) and the Human Connectome Project (http:// humanconnectome.org). They are designed to use advances in neuroimaging while simultaneously collecting in-depth phenotypic and genotypic data from cohorts of healthy subjects, and in some instances following subjects longitudinally. Their outcome will provide a rich platform for future investigations linking structural and functional vulnerability and resilience to disease. They should also afford the chance to develop early-life interventions for improved well-being or better 'brain resilience' , as perhaps illustrated in a recent study highlighting the benefits of yoga on brain circuits linked to increased pain tolerance 91 .
The desire to identify and understand the biological underpinning of risk factors is often motivated by the hope for more targeted or preventative treatments. Indeed, in the case of chronic pain it may be possible to use a combination of brain-related measures, quantitative sensory testing and genotyping to aid stratification and improve treatment selection and targeting of interventions. We are not there yet, but recent imaging data points toward this being feasible 60 . Finally, however, it is important to remember that stochastic and nonlinear, chaotic processes have a major role in a person's life. Smoking causes cancer, but is neither a necessary nor a sufficient factor 92 . The goal of predicting who will develop chronic pain and who will be spared is a worthy one, but whether this is achievable at an individual level remains to be seen.
